CNTA Centessa Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Centessa (CNTA)

Centessa Pharmaceuticals (CNTA) relies on a decentralized system of laboratories to discover treatments for orphan diseases. The percentage change in quarterly EPS demonstrates efficiency dynamics, where the -161.90 level reflects the current magnitude. Development is hindered by strict FDA oversight and high R&D costs; however, stability is maintained by a significant capital reserve and positive clinical trial results.

Centessa (CNTA) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 07/04/2026

Analytical breakdowns for Centessa Pharmaceuticals

Fundamental company analysis:centessa.com, CNTA
Manufactured product of Centessa Corp

Fundamental analysis of this asset requires minimizing uncertainty by monitoring net income dynamics. For Centessa Pharmaceuticals (CNTA), with its asset-light model and outsourced production, such fluctuations reflect the efficiency of contract manufacturing management. The quarterly EPS growth trajectory measures the percentage change in earnings per share relative to the previous period. This indicator reveals the gap between actual returns and market expectations, allowing for an objective assessment of the company's capital stability.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Dyne Therapeutics (DYN)|EWTX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata